Treatment with RANKL alone did not induce a significant change in the expression of IL-1β (Fig. 4a, b), MMP-3 (Fig. 4c, d), and MMP-13 (Fig. 4e, f) by both AF and NP cells. This evidence concerns the gene MMP13 and atrial fibrillation.